Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC
Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.
Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses results from the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer (CRC).
During a presentation at the 2019 Gastrointestinal Cancers Symposium, an overall survival benefit of approximately 2.5 months was found in patients with microsatellite-stable CRC.
This is exciting as it is the first finding, according to Wadlow, that shows a statistically significant improvement with a checkpoint inhibitor in the majority of this patient population.
See more from the 2019 Gastrointestinal Cancers Symposium.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
